HOLON, Israel, April 30, 2018 /PRNewswire/ --
Compugen Ltd. (NASDAQ: CGEN), a leader in predictive discovery
and development of first-in-class therapeutics for cancer
immunotherapy, announced today that the Company will release its
first quarter 2018 financial results on Wednesday, May 9, 2018 before the U.S. financial
markets open. Management will host a live webcast to review the
results and provide a corporate update at 10:00 AM ET.
To access the live conference call by telephone, please dial
1-888-407-2553 from the U.S., or +972-3-918-0610 internationally.
The call will also be available via live webcast through Compugen's
website, located at the following link. Following the live audio
webcast, a replay will be available on the Company's website.
About Compugen
Compugen is a therapeutic discovery and development company
utilizing its broadly applicable predictive discovery
infrastructure to identify novel drug targets and develop
first-in-class therapeutics in the field of cancer immunotherapy.
The Company's therapeutic pipeline consists of immuno-oncology
programs against novel drug targets it has discovered, including T
cell immune checkpoints and myeloid target programs. Compugen's
business model is to selectively enter into collaborations for its
novel targets and related drug product candidates at various stages
of research and development. The Company is headquartered in
Israel, with R&D facilities in
both Israel and South San Francisco, CA. Compugen's shares are
listed on NASDAQ and the Tel Aviv Stock Exchange under the ticker
symbol CGEN. For additional information, please visit Compugen's
corporate website at http://www.cgen.com.
Company contact:
Elana Holzman
Director, Investor Relations and Corporate Communications
Compugen Ltd.
Email: elanah@cgen.com
Tel: +972(3)765-8124
Investor Relations contact:
Burns McClellan, Inc.
Jill Steier
Email: jsteier@burnsmc.com
Tel: +1-212-213-0006
SOURCE Compugen Ltd.